Renal Specialist formulary list
**Other indications for particular drugs may be included on completion of further specialist lists**
The following medicines are approved for prescribing by or on the recommendation of a prescribing renal specialist:
MEDICINE | SUMMARY OF RESTRICTED INDICATION | CATEGORY | PROTOCOL |
Tinzaparin | Anticoagulation during haemodialysis. |
![]() |
|
Danaparoid | Anticoagulation during haemodialysis in patients who develop heparin-induced thrombocytopenia (HIT). |
![]() |
|
Argatroban | Anticoagulation during haemodialysis in adult patients with heparin-induced thrombocytopenia (HIT) type II who require parenteral antithrombotic therapy. For use in renal failure only. Second line after danaparoid (persistent HIT or adverse reaction with danaparoid). |
![]() |
|
Cyclophosphamide injection | Rapidly progressive glomerulonephritis (RPGN), severe systemic vasculitis, (including ANCA associated vasculitis (active granulomatosis with polyangiitis (Wegener’s) (GPA) and microscopic polyangiitis (MPA)), management of nephrotic syndrome. |
![]() |
Cyclophosphamide protocol (NHS Tayside Staffnet intranet link only) |
|
Rapidly progressive glomerulonephritis (RPGN), severe systemic vasculitis, (including ANCA associated vasculitis (active granulomatosis with polyangiitis (Wegener’s) (GPA) and microscopic polyangiitis (MPA)), management of nephrotic syndrome. |
![]() |
Cyclophosphamide protocol (NHS Tayside Staffnet intranet link only) |
Mycophenolate mofetil | Immunosuppression in kidney transplant* |
![]() |
See EdRen renal transplant handbook (Edinburgh Royal Infirmary Renal Unit) See Tayside Prescriber DTC Supplement No 115 – Mycophenolate Mofetil generic switch |
Tacrolimus (Prograf®/ Advagraf®) |
Immunosuppression in kidney transplant* |
![]() |
|
Azathioprine |
|
![]() |
|
Ciclosporin (Neoral®/ Sandimmun®) |
|
![]() |
|
Sirolimus |
|
![]() |
|
Rituximab (MabThera®) concentrate for intravenous infusion | In combination with glucocorticoids for induction of remission in severe, active granulomatosis with polyangiitis (Wegener’s) (GPA) and microscopic polyangiitis (MPA) in patients who have relapsed following cyclophosphamide or who are intolerant to or unable to receive cyclophosphamide. |
![]() |
|
Iron sucrose (Venofer®) | Renal anaemia. First choice parenteral iron preparation. |
![]() |
Anaemia guidelines in Chronic Kidney Disease under review |
Ferric carboxymaltose (Ferinject®) | Renal anaemia. Restricted to pre-dialysis patients. |
![]() |
|
Darbepoetin alfa (Aranesp®) | Renal anaemia. First choice erythropoiesis stimulating agent. |
![]() |
|
Epoetin beta (NeoRecormon®) |
|
![]() |
|
Methoxy polyethylene glycol-epoetin beta (Micera®) |
|
![]() |
|
Sodium bicarbonate 500mg capsules | Chronic acidotic states |
![]() |
Electrolyte replacement guidelines
|
Potassium citrate mixture BP (approx. 1mmol/mL of citrate) | Reduction of renal stone formation including patients with hypocitraturia and renal tubular acidosis (unlicensed use ‘off-label’) |
![]() |
|
Potassium citrate 1080mg tablets (10mmol of citrate) (unlicensed) (imported via Mawdsleys or IDIS) | Reduction of renal stone formation including patients with hypocitraturia and renal tubular acidosis if potassium citrate mixture not tolerated. |
![]() |
|
Calcium acetate (Phosex®) | Hyperphosphataemia. First choice phosphate-binding agent |
![]() |
Guidelines for the Management of Bone Metabolism and Disease in Chronic
Kidney Disease
(NHS Tayside
Staffnet intranet link only) |
Calcium acetate (PhosLo®) | Hyperphosphataemia |
![]() |
|
Calcium carbonate
(Calcichew |
Hyperphosphataemia |
![]() |
|
Sevelamer carbonate (Renvela®) | First-choice non-calcium based phosphate-binding agent for hyperphosphataemia in patients on haemodialysis or peritoneal dialysis and patients with CKD not on dialysis with serum phosphate concentration of 1.78mmol/L or more. |
![]() |
|
Sevelamer hydrochloride (Renagel®) | Hyperphosphataemia in patients on haemodialysis or peritoneal dialysis. |
![]() |
|
Lanthanum (Fosrenol®) | Hyperphosphataemia in CKD (dependant upon serum calcium and PTH levels). Used in patients intolerant to sevelamer. |
![]() |
|
Cinacalcet |
|
![]() |
Guidelines for the Management of Bone Metabolism and Disease in Chronic
Kidney Disease
(NHS Tayside Staffnet intranet link only) |
Magnesium
glycerophosphate 1g tablets (unlicensed) (made by UCLH, ordered from IDIS) |
Hypomagnesaemia |
![]() |
Electrolyte replacement guidelines |
Alfacalcidol | Vitamin D deficiency and/or secondary hyperparathyroidism |
![]() |
Guidelines for the Management of Bone Metabolism and Disease in Chronic Kidney Disease (NHS Tayside Staffnet intranet link only) Renal bone disease guidance due for review |
Valganciclovir (Valcyte®) | Given for 200 days post-transplant for prevention of CMV disease in all transplant recipients except CMV-negative recipients of CMV-negative donors* |
![]() |
See EdRen renal transplant handbook (Edinburgh Royal Infirmary Renal Unit) |
Hepatitis B vaccine ((HBvaxPRO®) | Immunisation against hepatitis B infection in patients with CKD including those on haemodialysis |
![]() |
Immunisation against infectious disease – ‘The Green Book’ Renal Hepatitis B vaccination guidance under development |
*= initiated by a tertiary transplant centre
Traffic light status information | |
![]() |
To be prescribed by Hospital Specialists Only. |
![]() |
Can be prescribed in General Practice under the direction of a Specialist. |
Click here for a link to the NHS Tayside Adult Empirical Treatment of Infection Guidelines for Renal Patients (NHS Tayside Staffnet intranet link only).
© 2010 NHS Tayside